(Q33370701)

English

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

O'Sullivan JM

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Norman AR

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

McCready VR

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Flux G

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Buffa FM

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Johnson B

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Coffey J

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cook G

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Treleaven J

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Horwich A

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Huddart RA

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Parker CC

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dearnaley DP

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

30 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1055-1061

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-005-0010-5

21 January 2018

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-005-0010-5

21 January 2018

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

1 reference

https://api.crossref.org/works/10.1007%2FS00259-005-0010-5

21 January 2018

Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy and radiotherapy for advanced testicular non-seminoma. I. The influence of sequence and timing of drugs and radiation on the appearance of normal tissue damage

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The management of hormone-relapsed prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternating chemotherapy and radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The challenge of locally advanced prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency

1 reference

https://pubmed.ncbi.nlm.nih.gov/16572306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-005-0010-5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33370701&oldid=2195294350"